Enterprise Value
250.2K
Cash
25.45M
Avg Qtr Burn
-10.9M
Short % of Float
8.92%
Insider Ownership
1.07%
Institutional Own.
26.77%
Qtr Updated
12/31/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CB-1158 (INCB00158) (Arginase Inhibitor) Details Solid tumors | Phase 1/2 Data readout | |
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Phase 1/2 Update | |
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Non-small cell lung carcinoma, Solid tumor/s | Failed Discontinued | |
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma | Failed Discontinued | |
CB-659 (mivavotinib) Details Non-Hodgkin lymphoma, Diffuse large B cell lymphoma | Failed Discontinued | |
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma, Cancer | Failed Discontinued |